The theranostics market was valued at USD 2.36 billion in 2025 and is projected to grow from USD 2.72 billion in 2026 to USD 8.67 billion by 2034, at a CAGR of 15.5% from 2026 to 2034, according to Polaris Market Research. The report describes theranostics as the integration of therapeutic and diagnostic approaches to provide personalized treatments, combining diagnostic tests such as imaging and biomarker assays with targeted therapies to optimize patient outcomes. North America was the largest market in 2025.

Reagents and Software Shape Product Demand

Reagents held the largest product type share, at 47.9% in 2025, owing to their critical role in diagnostic tests and molecular diagnostic applications. They are essential for the tests that guide personalized therapeutic strategies, and the segment benefits from new assays that enable more accurate disease detection, particularly in oncology. Software, by contrast, is registering the highest growth at 15.4% during the forecast period, driven by reliance on data analytics and artificial intelligence to interpret diagnostic results and inform treatment decisions. Instruments complete the product type segmentation.

Genomics, Sequencing, and Proteomics

By technology, genomics accounted for a major share of 48.3% in 2025. Next-generation sequencing has revolutionized the approach to precision medicine, allowing more accurate diagnoses and personalized treatment strategies, and the falling cost of genomic testing is making it more accessible to healthcare providers. Proteomics is registering the fastest growth at 15.8%, fueled by advances that enable detailed study of proteins and their functions in disease. It plays a critical role in identifying novel biomarkers and understanding disease mechanisms, which supports the development of targeted therapies. Metabolomics and biomarkers complete the technology segmentation.

Genomic technologies allow the sequencing and analysis of an individual's genetic makeup, enabling identification of specific biomarkers associated with disease, particularly in oncology. In Asia Pacific, China, Japan, and India lead expansion on rising healthcare expenditures and greater adoption of precision medicine.

Hospitals and Laboratories Lead Different Dimensions

Hospitals dominated end-user revenue with a 48.3% share in 2025, reflecting their central role in patient care and their ability to integrate advanced diagnostic and therapeutic technologies, particularly in oncology and cardiology. Diagnostic laboratories are registering the fastest growth at 15.9%, fueled by demand for early disease detection and personalized treatment strategies, the growing prevalence of chronic diseases, and the expansion of diagnostic services in developed and emerging markets. Research institutes form the third end-user group.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market 

AI, Regional Strength, and Competitive Strategy

AI-driven platforms are significantly enhancing the market. According to Polaris, they can analyze genomic profiles and patient data to identify biomarkers and predict treatment responses more efficiently, support optimized radiopharmaceutical dosing and real-time disease monitoring, reduce diagnostic errors, and improve workflow efficiency.

Europe captured a 28.0% share in 2025, driven by investment in precision medicine, regulatory support, and the rising prevalence of chronic diseases, with Germany, the UK, and France at the forefront. Government initiatives promoting biomarker research are also supporting growth.

Competition centers on innovation and collaboration. Thermo Fisher Scientific contributes technologies such as PCR, immunohistochemistry, in situ hybridization, and sequencing, while Siemens Healthineers expanded its portfolio through the purchase of Advanced Accelerator Applications from Novartis. Polaris notes that regulatory approvals and reimbursement policies strongly influence adoption, and partnerships between pharmaceutical companies, diagnostic firms, and healthcare providers help integrate these solutions into clinical practice.

Other portfolio moves illustrate the pattern. Lantheus Holdings acquired global rights to novel radiopharmaceuticals to broaden its oncology offerings. GE HealthCare, which invests over USD 1 billion annually in research and development, spans imaging, advanced visualization, patient care, and pharmaceutical diagnostics, and offers AI-enabled digital solutions that enhance clinical insights and operational efficiency.

Key Players

• Abbott Laboratories
• Advanced Accelerator Applications
• Astellas Pharma Inc.
• Bayer AG
• Cardinal Health, Inc.
• Curium Pharma
• Hoffmann-La Roche AG
• GE HealthCare Technologies Inc.
• Illumina, Inc.
• Lantheus Holdings, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Conclusion

Growth in the theranostics market is being shaped as much by enabling technologies as by clinical demand. Reagents remain the largest product category, next-generation sequencing anchors the technology mix, and proteomics is the fastest-growing area. Diagnostic laboratories are expanding quickly, and AI-driven platforms are raising the value of every data point generated. B2B stakeholders should align portfolios and partnerships with these building blocks and monitor reimbursement and regulatory developments closely.

More Trending Latest Reports By Polaris Market Research:

Public Transportation Market

Pharmacy Automation Devices Market

Dispersing Agent Market

Insulated Packaging Market

Quality Management Software (Qms) Market

Lithium-Ion Battery Cathode Market

Lithium-Ion Battery Cathode Market

Dispersing Agent Market

Nuclear Power Plant Equipment Market